Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...

Scientists at Florida International University may have found a way to make a powerful cancer treatment work even better. The ...

Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation ...

Certain white blood cells in the immune system, known as neutrophils, can make cancer immunotherapy less effective, according ...

Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand could make it even more effective ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

T cells are some of the immune system's most important warriors. They can stop tumor growth and even fight off severe ...

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted immune therapies to expand specific CD8 T-cells in vivo, today presented new interim data ...

Engineered cell products such as CAR T cells have demonstrated considerable therapeutic potential. Two studies in Science report new avenues to expand the applications of synthetic cell therapies – ...